These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2101410)

  • 21. Skin involvement in Hodgkin's disease.
    Perifanis V; Sfikas G; Tziomalos K; Sotiriadis D; Garipidou V
    Cancer Invest; 2006; 24(4):401-3. PubMed ID: 16777693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
    Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
    Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of Hodgkin's disease with lesions of the mediastinal lymph nodes and involvement in pulmonary processes].
    Baĭsogolov GD; Afanasova NV; Shakhtarina SV
    Med Radiol (Mosk); 1990 May; 35(5):10-3. PubMed ID: 2342405
    [No Abstract]   [Full Text] [Related]  

  • 24. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
    Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
    Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3].
    Diehl V; Pfreundschuh M; Löffler M; Smith K; Rühl U; Georgii A; Hiller E; Gerhartz H
    Onkologie; 1987 Apr; 10(2):62-6. PubMed ID: 2438613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presumed intraocular Hodgkin's disease.
    Bishop JE; Salmonsen PC
    Ann Ophthalmol; 1985 Sep; 17(9):589-92. PubMed ID: 4062168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Leuk Lymphoma; 1994 Jun; 14(1-2):79-89. PubMed ID: 7522721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary cutaneous Hodgkin's lymphoma.
    Mukesh M; Shuttleworth D; Murray P
    Clin Exp Dermatol; 2009 Dec; 34(8):e673-5. PubMed ID: 19817768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nodular sclerosing Hodgkin's disease with massive skin invasion.
    Tanaka K; Yonekura S; Nagao T; Kubota T; Usui T; Ohbayashi Y; Satou Y; Komatsuda M; Arimori S
    Tokai J Exp Clin Med; 1986 Aug; 11(3):213-8. PubMed ID: 3617106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
    Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM
    J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intermediate results of the German Hodgkin's disease therapy study].
    Onkologie; 1986 Jun; 9(3):159-62. PubMed ID: 2427983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.